收费全文 | 2796090篇 |
免费 | 378588篇 |
国内免费 | 43874篇 |
耳鼻咽喉 | 36194篇 |
儿科学 | 88399篇 |
妇产科学 | 73184篇 |
基础医学 | 420607篇 |
口腔科学 | 71659篇 |
临床医学 | 278939篇 |
内科学 | 579760篇 |
皮肤病学 | 65718篇 |
神经病学 | 230949篇 |
特种医学 | 107970篇 |
外国民族医学 | 736篇 |
外科学 | 419721篇 |
综合类 | 97734篇 |
现状与发展 | 5篇 |
一般理论 | 970篇 |
预防医学 | 227624篇 |
眼科学 | 72684篇 |
药学 | 237921篇 |
11篇 | |
中国医学 | 52009篇 |
肿瘤学 | 155758篇 |
2021年 | 23242篇 |
2019年 | 33849篇 |
2018年 | 43021篇 |
2017年 | 36990篇 |
2016年 | 39238篇 |
2015年 | 42351篇 |
2014年 | 53107篇 |
2013年 | 72963篇 |
2012年 | 92600篇 |
2011年 | 98242篇 |
2010年 | 66690篇 |
2009年 | 69951篇 |
2008年 | 90339篇 |
2007年 | 92023篇 |
2006年 | 93102篇 |
2005年 | 89259篇 |
2004年 | 88283篇 |
2003年 | 84822篇 |
2002年 | 81989篇 |
2001年 | 137654篇 |
2000年 | 137173篇 |
1999年 | 119844篇 |
1998年 | 40848篇 |
1997年 | 36426篇 |
1996年 | 36691篇 |
1995年 | 36086篇 |
1994年 | 33667篇 |
1993年 | 31250篇 |
1992年 | 92785篇 |
1991年 | 88866篇 |
1990年 | 85554篇 |
1989年 | 82768篇 |
1988年 | 76103篇 |
1987年 | 74051篇 |
1986年 | 69251篇 |
1985年 | 65680篇 |
1984年 | 48919篇 |
1983年 | 42008篇 |
1982年 | 27249篇 |
1981年 | 24522篇 |
1979年 | 43345篇 |
1978年 | 31410篇 |
1977年 | 27386篇 |
1976年 | 25274篇 |
1975年 | 26465篇 |
1974年 | 30471篇 |
1973年 | 28817篇 |
1972年 | 27248篇 |
1971年 | 24978篇 |
1970年 | 23053篇 |
Research design and methods: This multicenter, open-label, single-group, prospective interventional study evaluated changes in total gait-related scores of the Part II/III Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and Freezing of Gait Questionnaire (FOG-Q) in 31 Parkinson’s disease patients treated with istradefylline. Gait analysis by portable gait rhythmogram was performed.
Results: MDS-UPDRS Part III gait-related total scores significantly decreased at Weeks 4–12 from baseline with significant improvements in gait, freezing of gait, and postural stability. Significant decreases in MDS-UPDRS Part II total scores and individual item scores at Week 12 indicated improved daily living activities. At Week 12, there were significant improvements in FOG-Q, new FOG-Q, and overall movement per 48 h measured by portable gait rhythmogram. Adverse events occurred in 7/31 patients.
Conclusions: Istradefylline improved gait disorders in Parkinson’s disease patients complicated with freezing of gait, improving their quality of life. No unexpected adverse drug reactions were identified.
Trial registration: UMIN-CTR (UMIN000020288). 相似文献
Areas covered: This article reviews the major preclinical and clinical data on PDE5 inhibitors with a specific focus on tadalafil. It includes details of the role of the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) – PDE5 pathway in the LUT organs (bladder and prostate) in addition to the available data on tadalafil in patients with LUTS secondary to BPH with or without erectile dysfunction (ED).
Expert opinion: Preclinical and clinical data have clearly demonstrated that PDE5 inhibitors induce bladder and prostate relaxation, which contributes to the improvement seen in storage symptoms in both animal models of bladder and prostate hypercontractility. Tadalafil is effective both as a monotherapy and add-on therapy in patients with LUTS secondary to BPH. Furthermore, as LUTS-BPH and ED are urological disorders that commonly coexist in aging men, tadalafil is more advantageous than α1-adrenoceptors and should be used as the first option. Tadalafil is a safe and tolerable therapy and unlike α1- adrenoceptors and 5-alpha reductase inhibitors, which can cause sexual dysfunctions, tadalafil improves sexual function. 相似文献